Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh, Markus Loeffler, Bernd Metzner et al.|The Lancet Oncology|2008Cited by 1.1k
Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized ProcessWolfgang Wagner, Anthony D. Ho|PLoS ONE|2008Cited by 1.1k
Aging and Replicative Senescence Have Related Effects on Human Stem and Progenitor CellsWolfgang Wagner, Anthony D. Ho|PLoS ONE|2009Cited by 477
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Rüdiger Hehlmann, Michael Lauseker et al.|Leukemia|2017Cited by 339
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus et al.|Blood|2011Cited by 289